Hematology
From the Journals
Global blood supply runs low
Worldwide, more than 60% of countries had an inadequate supply of blood to meet the demand for transfusion.
News from the FDA/CDC
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.
From the Journals
Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS
Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists.
Feature
Readmission burden high for those with sickle cell disease
SCD more than doubles the risk of 30-day readmission, compared with non-SCD stays.
From the Journals
New consensus recommendations on bleeding in acquired hemophilia
The key areas addressed in the global expert consensus statement include the initial management of bleeding and management of location-specific...
From the Journals
Hemophilia prevalence is nearly three times higher than previously reported
Dr. J. Michael Soucie of the Centers for Disease Control and Prevention said having more accurate prevalence data will help improve access to care...
Feature
Ongoing research aims to improve transplant outcomes in sickle cell
Over the past 2 years, the majority of novel transplant techniques have been primarily aimed at improving conditioning regimens and lowering rates...
Conference Coverage
Early post-ACS bleeding may signal cancer
PARIS – Cancer risk is elevated with bleeding, whether or not DAPT is employed
Guidelines
ACOG advises bleeding disorder screening for teens with heavy menstruation
Bleeding disorders are found in approximately 20% of adolescent girls who present for evaluation of heavy menstrual bleeding and in 33% of...
Pearl of the Month
How thin should we go?
Dr. Douglas S. Paauw describes the best approach to anticoagulation in patients with atrial fibrillation who are on anticoagulation, then have a...
Conference Coverage
RNA interference drug fitusiran looks effective in both hemophilia A and B
MELBOURNE – The RNA interference drug fitusiran is associated with significant reductions in bleeding rates in patients with hemophilia A and B,...